267 related articles for article (PubMed ID: 25522383)
1. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor.
Smith JA; Bourdet DL; Daniels OT; Ding YS; Gallezot JD; Henry S; Kim KH; Kshirsagar S; Martin WJ; Obedencio GP; Stangeland E; Tsuruda PR; Williams W; Carson RE; Patil ST
Int J Neuropsychopharmacol; 2014 Dec; 18(2):. PubMed ID: 25522383
[TBL] [Abstract][Full Text] [Related]
2. Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat.
Bourdet DL; Tsuruda PR; Obedencio GP; Smith JA
J Pharmacol Exp Ther; 2012 Apr; 341(1):137-45. PubMed ID: 22235148
[TBL] [Abstract][Full Text] [Related]
3. Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults.
Matuskey D; Gallezot JD; Nabulsi N; Henry S; Torres K; Dias M; Angarita GA; Huang Y; Shoaf SE; Carson RE; Mehrotra S
J Psychopharmacol; 2023 Feb; 37(2):164-171. PubMed ID: 36515395
[TBL] [Abstract][Full Text] [Related]
4. Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography.
Comley RA; Salinas CA; Slifstein M; Petrone M; Marzano C; Bennacef I; Shotbolt P; Van der Aart J; Neve M; Iavarone L; Gomeni R; Laruelle M; Gray FA; Gunn RN; Rabiner EA
J Pharmacol Exp Ther; 2013 Aug; 346(2):311-7. PubMed ID: 23685546
[TBL] [Abstract][Full Text] [Related]
5. Relative contributions of norepinephrine and serotonin transporters to antinociceptive synergy between monoamine reuptake inhibitors and morphine in the rat formalin model.
Shen F; Tsuruda PR; Smith JA; Obedencio GP; Martin WJ
PLoS One; 2013; 8(9):e74891. PubMed ID: 24098676
[TBL] [Abstract][Full Text] [Related]
6. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
[TBL] [Abstract][Full Text] [Related]
7. SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study.
Takano A; Halldin C; Farde L
Psychopharmacology (Berl); 2013 Mar; 226(1):147-53. PubMed ID: 23090625
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836.
Zheng M; Appel L; Luo F; Lane R; Burt D; Risinger R; Antoni G; Cahir M; Keswani S; Hayes W; Bhagwagar Z
Psychopharmacology (Berl); 2015 Feb; 232(3):529-40. PubMed ID: 25116481
[TBL] [Abstract][Full Text] [Related]
9. The extracts of Fructus Akebiae, a preparation containing 90% of the active ingredient hederagenin: serotonin, norepinephrine and dopamine reuptake inhibitor.
Jin ZL; Gao N; Zhou D; Chi MG; Yang XM; Xu JP
Pharmacol Biochem Behav; 2012 Jan; 100(3):431-9. PubMed ID: 22005599
[TBL] [Abstract][Full Text] [Related]
10. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD.
Ding YS; Naganawa M; Gallezot JD; Nabulsi N; Lin SF; Ropchan J; Weinzimmer D; McCarthy TJ; Carson RE; Huang Y; Laruelle M
Neuroimage; 2014 Feb; 86():164-71. PubMed ID: 23933039
[TBL] [Abstract][Full Text] [Related]
11. Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.
Zhao Z; Zhang HT; Bootzin E; Millan MJ; O'Donnell JM
Neuropsychopharmacology; 2009 May; 34(6):1467-81. PubMed ID: 18923402
[TBL] [Abstract][Full Text] [Related]
12. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
Verrico CD; Miller GM; Madras BK
Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
[TBL] [Abstract][Full Text] [Related]
13. Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2).
Nogami T; Takano H; Arakawa R; Ichimiya T; Fujiwara H; Kimura Y; Kodaka F; Sasaki T; Takahata K; Suzuki M; Nagashima T; Mori T; Shimada H; Fukuda H; Sekine M; Tateno A; Takahashi H; Ito H; Okubo Y; Suhara T
Int J Neuropsychopharmacol; 2013 Jun; 16(5):937-43. PubMed ID: 23067569
[TBL] [Abstract][Full Text] [Related]
14. A novel serotonin transporter ligand: (5-iodo-2-(2-dimethylaminomethylphenoxy)-benzyl alcohol.
Zhuang Z; Choi S; Hou C; Mu M; Kung M; Acton PD; Kung HF
Nucl Med Biol; 2000 Feb; 27(2):169-75. PubMed ID: 10773546
[TBL] [Abstract][Full Text] [Related]
15. An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine.
Frankle WG; Robertson B; Maier G; Paris J; Asmonga D; May M; Himes ML; Mason NS; Mathis CA; Narendran R
Synapse; 2018 Mar; 72(3):. PubMed ID: 29216407
[TBL] [Abstract][Full Text] [Related]
16. Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.
Talbot PS; Bradley S; Clarke CP; Babalola KO; Philipp AW; Brown G; McMahon AW; Matthews JC
Neuropsychopharmacology; 2010 Feb; 35(3):741-51. PubMed ID: 19890256
[TBL] [Abstract][Full Text] [Related]
17. [Studies on Monoamine Transporter Occupancy of Antidepressants using PET: Focusing on SERT and NET].
Matsuyama S; Arakawa R; Asami Y
Brain Nerve; 2021 Jun; 73(6):731-736. PubMed ID: 34127569
[TBL] [Abstract][Full Text] [Related]
18. Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2.
Moriguchi S; Takano H; Kimura Y; Nagashima T; Takahata K; Kubota M; Kitamura S; Ishii T; Ichise M; Zhang MR; Shimada H; Mimura M; Meyer JH; Higuchi M; Suhara T
Int J Neuropsychopharmacol; 2017 Dec; 20(12):957-962. PubMed ID: 29016875
[TBL] [Abstract][Full Text] [Related]
19. SEP-225289 serotonin and dopamine transporter occupancy: a PET study.
DeLorenzo C; Lichenstein S; Schaefer K; Dunn J; Marshall R; Organisak L; Kharidia J; Robertson B; Mann JJ; Parsey RV
J Nucl Med; 2011 Jul; 52(7):1150-5. PubMed ID: 21680689
[TBL] [Abstract][Full Text] [Related]
20. The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics.
Zhu Z; Guo N; Narendran R; Erritzoe D; Ekelund J; Hwang DR; Bae SA; Laruelle M; Huang Y
Nucl Med Biol; 2004 Nov; 31(8):983-94. PubMed ID: 15607480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
